Asthma attacks all age groups but often starts in childhood. It isa disease characterized by recurrent attacks of breathlessness and wheezing, which vary in severity and frequency from person to person. According to WHO Between 100 and 150 million people around the globe -- roughly the equivalent of the population of the Russian Federation -- suffer from asthma and this number is rising. World-wide, deaths from this condition have reached over 180,000 annually. Asthma and COPD are clinically defined airway disorders that individually have significant heterogeneity with regard to underlying pathogenesis and responses to therapy. Tiotropium is well tolerated, with a safety profile comparable with that of placebo. The parasympathetic nervous system plays an important role in autonomic control of airways and is believed to be largely responsible for resting but they bronchomotor tone in COPD. Hence the purpose of the present study was to evaluate the efficacy and safety of 18mcg Tiotropium metered dose inhalation, administered once daily for 14 weeks in patients with COPD and Bronchial asthma, cross over study with placebo. The over all results of our study suggests that Tiotropium in the dose of 18 mcg once daily via dry powder inhaler result in 24 h bronchodilation as well as consistent and sustained improvement for both the COPD and the bronchial asthma patients. It is safe and efficacious drug both clinically and spirometrically. Our study showed decrease in symptoms, decrease in rescue medication frequency and also reduce frequency of acute attacks.